Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
69
BBC Quote, Financials, Valuation and Earnings
Last price:
$40.24
Seasonality move
:
-3.31%
Day range:
$39.55 - $40.32
52-week range:
$13.42 - $40.82
Dividend yield:
1.63%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
32.2K
Avg. volume:
29.9K
1-year change:
64.63%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$40.24 | -- | -- | -- | $0.66 | 1.63% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$82.44 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$84.16 | -- | -- | -- | $0.42 | 0.97% | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
$18.12 | -- | -- | -- | $0.12 | 7.95% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$89.57 | -- | -- | -- | $0.02 | 0.08% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.29 | -- | -- | -- | $0.12 | 0.27% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.813 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.818 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | 0.378 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 1.031 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.960 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors
-
Which has Higher Returns BBC or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is BBC or BBP More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.974%.
-
Which is a Better Dividend Stock BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.63%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns BBC or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is BBC or PBE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.822, suggesting its less volatile than the S&P 500 by 17.787%.
-
Which is a Better Dividend Stock BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.63%. Invesco Biotechnology & Genome ETF offers a yield of 0.97% to investors and pays a quarterly dividend of $0.42 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns BBC or PFFR?
InfraCap REIT Preferred ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat InfraCap REIT Preferred ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- -
What do Analysts Say About BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand InfraCap REIT Preferred ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than InfraCap REIT Preferred ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than InfraCap REIT Preferred ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PFFRInfraCap REIT Preferred ETF0 0 0 -
Is BBC or PFFR More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison InfraCap REIT Preferred ETF has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.347%.
-
Which is a Better Dividend Stock BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.63%. InfraCap REIT Preferred ETF offers a yield of 7.95% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. InfraCap REIT Preferred ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than InfraCap REIT Preferred ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than InfraCap REIT Preferred ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while InfraCap REIT Preferred ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for InfraCap REIT Preferred ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- --
-
Which has Higher Returns BBC or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is BBC or XHE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.522%.
-
Which is a Better Dividend Stock BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.63%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns BBC or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is BBC or XHS More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, which suggesting that the stock is 1.702% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.625%.
-
Which is a Better Dividend Stock BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.63%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.27% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
